WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Merck and Pfizer initiate Phase III trial to evaluate Avelumab as first-line treatment for ovarian cancer 07 July 2016
Pfizer completes acquisition of Anacor 24 June 2016
Help Pfizer change the future of healthy aging 21 June 2016
Pfizer presents promising data from next generation ALK/ROS1 inhibitor in advanced non-small cell lung cancer 06 June 2016
Merck and Pfizer to present Avelumab data in seven different cancers at ASCO annual meeting 19 May 2016
Pfizer awards more than $1 million in metastatic breast cancer research funding 13 May 2016
Pfizer reports first-quarter 2016 results 03 May 2016
Pfizer announces termination of proposed combination with Allergan 07 April 2016
Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban) 30 March 2016
Pfizer celebrates a year of achievements in 2015 annual review 16 March 2016
Pfizer commences $5 billion accelerated share repurchase 11 March 2016
Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer 04 March 2016
Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction 08 February 2016
Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals 02 February 2016
Pfizer expands R&D equity investment strategy to access early-stage scientific innovations 13 January 2016
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer 04 January 2016
Global partners announce donation of 500 millionth dose of azithromycin 17 November 2015
Pfizer expands its patient assistance program 10 November 2015
Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline 06 October 2015
New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin 24 September 2015
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.